Oxford, UK - 7 September 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces positive ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced that the US Food and Drug Administration has approved DUAKLIR® PRESSAIR® (aclidinium ...
AstraZeneca Plc AZN announced positive top-line results from the phase III AMPLIFY study for Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily). The candidate is being evaluated for the ...
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
AstraZeneca has some positive new COPD data in hand—and it’s data that could help the company snag a new approval. The pharma giant expects to take those results right to regulators; it’s on track to ...
LONDON-A trial study using AstraZeneca PLC's (AZN.LN) drug Duaklir has significantly improved lung function in chronic obstructive pulmonary disease or COPD patients, the pharmaceutical company said ...
(RTTNews) - AstraZeneca (AZN.L, AZN) has agreed to transfer global rights to Eklira, and Duaklir to Covis Pharma Group. Covis will pay the company $270 million on completion. Eklira and Duaklir are ...
AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). Both ...
In 4Q17, AstraZeneca’s (AZN) Daliresp reported revenues of $53.0 million, which reflected ~29.0% year-over-year (or YoY) growth. In fiscal 2017, Daliresp generated revenues of $198.0 million, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results